ProPhase Labs, Inc. (PRPH)

Market Cap	147.43M
Revenue (ttm)	94.42M
Net Income (ttm)	6.52M
Shares Out	17.18M
EPS (ttm)	0.41
PE Ratio	20.93
Forward PE	10.09
Dividend	n/a
Ex-Dividend Date	May 24, 2022

Volume	147,769
Open	9.12
Previous Close	9.15
Day's Range	8.47 - 9.25
52-Week Range	6.60 - 15.25
Beta	-0.33
Analysts	Strong Buy
Price Target	14.00 (+63.17%)
Earnings Date	May 11, 2023

About PRPH

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 16, 1997
• Employees: 129
• Stock Exchange: NASDAQ
• Ticker Symbol: PRPH

Financial Performance

In 2022, ProPhase Labs's revenue was $122.65 million, an increase of 55.17% compared to the previous year's $79.04 million. Earnings were $18.46 million, an increase of 194.32%.

Analyst Forecast

According to one analyst, the rating for PRPH stock is "Strong Buy" and the 12-month stock price forecast is $14.0.

Price Target

$14.0

(63.17% upside)

Analyst Consensus: Strong Buy